Results of the OV4-1 Dual Satellite Experiment on Guided Ionospheric PropagationBarker · American Geophysical Union1970PDF1.1 MB
OV4: Chrysanthemum segetum-Spergula arvensis community: Spergulo-Chrysanthemetum segetum (Br.-Bl. & De Leeuw 1936) R. Tx. 1937Rodwell · British Plant Communities2000PDF190 KB
EXPRESSION III: Patient ́s Expectations and Preferences regarding Physician–Patient Relationship and Clinical Management. Results of the International NOGGO/ENGOT-ov4-GCIG study in 1,830 Ovarian Cancer Patients from European countries.Oskay-Özcelik · Annals of Oncology2018PDF387 KB
OV41: Parietaria diffusa community: Parietarietum judaicae (Arènes 1928) Oberdorfer 1977Rodwell2000PDF144 KB
OV40: Asplenium viride-Cystopteris fragilis community: Asplenio viridis-Cystopteridetum fragilis (Kuhn 1939) Oberdorfer 1949Rodwell · 10.1017/CB, 20002000PDF214 KB
ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancerFujiwara · Annals of Oncology2019PDF82 KB
ENGOT-ov43/keylynk-001: A Phase III, Placebo- and Active-controlled Trial of Pembrolizumab Plus Chemotherapy with Olaparib Maintenance for First-line Treatment of Advanced BRCA-nonmutated Epithelial Ovarian CancerColeman · Gynecologic Oncology2020PDF191 KB
ATHENA (GOG-3020/ENGOT-ov45): a Randomized, Phase III Trial to Evaluate Rucaparib as Monotherapy (ATHENA–MONO) and Rucaparib in Combination with Nivolumab (ATHENA–COMBO) as Maintenance Treatment Following Frontline Platinum-based Chemotherapy in Ovarian CancerMonk · International Journal of Gynecological Cancer2021PDF1.1 MB
A Phase III, Randomized, Double Blinded Trial of Platinum Based Chemotherapy with or Without Atezolizumab Followed by Niraparib Maintenance with or Without Atezolizumab in Patients with Recurrent Ovarian, Tubal, or Peritoneal Cancer and Platinum Treatment Free Interval of More Than 6 Months: ENGOT-Ov41/GEICO 69-O/ANITA TrialMartin · International Journal of Gynecological Cancer2020PDF632 KB
Poster exhibition Day 2 - P116 ATHENA (GOG-3020/ENGOT-ov45; EudraCT 2017–004557–17; NCT03522246): a randomised, double-blind, placebo-controlled, phase 3 study of the poly(ADP-Ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer (OC)Christopoulou2019PDF101 KB